Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the <scp>PIONEER</scp> phase 3 programme-Reference-Cited by-同舟云学术

Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme

Published:2022-05-09 Issue:7 Volume:24 Page:1338-1350
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Aroda Vanita R.¹^ORCID,Bauer Robert²,Christiansen Erik²,Haluzík Martin³^ORCID,Kallenbach Klaus²^ORCID,Montanya Eduard⁴^ORCID,Rosenstock Julio⁵^ORCID,Meier Juris J.⁶^ORCID

Affiliation:

1. Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA

2. Novo Nordisk A/S Søborg Denmark

3. Diabetes Centre Institute for Clinical and Experimental Medicine Prague Czech Republic

4. Hospital Universitari Bellvitge‐IDIBELL CIBERDEM and University of Barcelona Barcelona Spain

5. Dallas Diabetes Research Center at Medical City Dallas Texas USA

6. Department of Internal Medicine, Gastroenterology and Diabetology Augusta Clinic Bochum Germany

Funder

Korea Basic Science Institute

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14710

Reference37 articles.

1. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

2. Introduction: standards of medical care in diabetes‐2021;American Diabetes Association;Diabetes Care,2021

3. Duration of diabetes and types of diabetes therapy in Japanese patients with type 2 diabetes: The Japan Diabetes Complication and its Prevention prospective study 3 (JDCP study 3)

4. Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy

5. Race/Ethnic Difference in Diabetes and Diabetic Complications

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review;Cureus;2024-09-01

2. Efficacy and Safety of Escalating the Dose of Oral Semaglutide from 7 to 14 mg: A Single-Center, Retrospective Observational Study;Diabetes Therapy;2024-08-07

3. Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group;Diabetes Therapy;2024-07-11

4. Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity;Frontiers in Nutrition;2024-04-29

5. Therapy of Type 2 Diabetes;Experimental and Clinical Endocrinology & Diabetes;2024-04-10